Amphetamine Use Disorder denials in California external review

In the California DMHC record, independent physician reviewers decided 13 published external-review cases involving amphetamine use disorderand overturned the plan’s denial in 84.6%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
13
2005–2024
Overturned
84.6%
11 denials reversed

Most-fought treatments for amphetamine use disorder

What insurers denied — and how those fights ended.
CategoryDecisionsOverturned
Residential Treatment Center10
100%
Typical time to a decision
14 days
Most land between 5 and 21 days
Handled as urgent
46.2%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement and prospective authorization and coverage for residential treatment center (RTC) services equivalent to ASAM 3.1. For Dimension 1, The patient’s urine toxicology screening on admission was positive for amphetamine, fentanyl, methamphetamine, and tetrahydrocannabinol (THC). The patient was placed on medications for detoxification, including a lorazepam taper, clonidine, gabapentin, Suboxone, and promethazine. The patient is experiencing or anticipated to imminently experience moderately severe to severe signs and/or symptoms of intoxication that otherwise meet Intoxication and Associated Risks Criteria for treatment at Level 2.7 and the patient requires after-hours medical management and/or nursing care.
Medical Necessity · 2024 · IMR MN24-42204
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement and prospective authorization and coverage for residential treatment center (RTC) services (ASAM 3.1). Per the American Society of Addiction Medicine (ASAM) criteria, this patient meets Level 3.1 criteria for RTC services. ASAM criteria focus on six dimensions to determine the appropriate level of care, which includes: (1)intoxication and withdrawal potential; (2)biomedical conditions; (3)emotional, behavioral, and cognitive conditions; (4)readiness to change; (5)relapse, continued use, or continued problem potential; and (6)recovery environment. Based on ASAM criteria, this patient meets the requirements for ASAM 3.1 RTC services. For dimension 1, the patient was not intoxicated upon admission.
Medical Necessity · 2024 · IMR MN24-40910

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for residential substance abuse treatment he received. Findings: The physician reviewer found that, to objectively determine if the patient met the criteria for residential substance abuse treatment, the Level of Care Utilization System (LOCUS) guidelines are applicable. This is an accepted, national standard for determining the appropriate level of care for adults. On the date of service in question, the patient demonstrated a low risk of harm (score 2) as there was no documentation of prior suicide attempts and the patient did not have any suicidal ideation on that date.
Medical Necessity · 2018 · IMR MN18-27287
The patient is a 23-year-old female with approximately a two-year history of bulimia nervosa with episodes of binging and purging up to three times per day. Each binge lasted one to two hours with the patient sometimes eating to the point of physical pain. The patient also noted having grown increasingly depressed in the seven months prior to admission following the breakup of a relationship with her boyfriend, with subsequent lethargy, increasing social isolation, and irritability. This was compounded by her use of amphetamine, particularly flagrant in the three to four months prior to her inpatient admission in October 2002.
Medical Necessity · 2005 · IMR MN05-4554

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving amphetamine use disorder, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for amphetamine use disorder? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9